- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02915757
Electrodermal Hyporeactivity And Depression (EUDOR-A)
Naturalistic Clinical Studies in Several Centres of Electrodermal Hyporeactivity in Adult Patients With Primary Depression
Study Overview
Detailed Description
This EUDOR-A study is a naturalistic, european and multicentric study. In France, patient's recruitment will be only conducted by investigators within the Department of Psychiatric Emergencies and Post Acute Care, University Hospital of Montpellier.
Over one year, 233 patients suffering from a major depressive episode with (n=70) and without any history of suicide attempt (n=163) will be recruited.
The maximum period of participation for a given patient will be 12 months with 2 phone assessments at 6 month and 12 month.
Inclusion visit: clinical and biological assessment and Edor test. Second and third visits at 6 and 12 month: Follow up visits in the department or interview by telephone in order to assess suicidal ideations or suicide attempts since the inclusion.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Montpellier, France, 34295
- Montpellier University Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion criteria:
All subjects men and women will necessarily meet the following inclusion criteria:
- In- and outpatients, with a diagnosis of primary depression according to the International classification of Disease (ICD-10) should be included as a routine. That is, patients in a primary unipolar major episode or dysthymia or primary depression with a personality disorder or an anxiety disorder as secondary diagnoses and primary bipolar disorder in a non-hypomanic and non-manic phase are expected to be included.
- Age : 18 years or older
- written informed consent
- must belong to social safety system
- To be able to understand instructions for the EDOR Test, the aim and the methodology of the study.
Exclusion criteria:
- diagnosed or suspected dementia
- Acute known or suspected alcohol or other substance abuse. The condition of past substance abuse (i.e. alcohol abuse or dependance, drug abuse or dependance ) should be noted in the comment field of the EDOR Test routine and patient must have been abstinent for at least one year.
- Serious problems of hearing, the patient should not participate.
- Refusal of participation
- Subject deprived of liberty (by judicial or administrative decision)
- Subject protected by law.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Depressive patients
EDOR test on depressed patients with or without personal history of suicidal behavior
|
The ElectroDermal Orienting Reactivity (EDOR) specifically is optimized for the detection of electrodermal hyporeactivity. The EDOR investigation last about 30 min. The EDOR Test Data is sent immediately after each EDOR Test for each Test Person to a Company named EMOTRA for blind analyses. The EDOR Test Report may change the basis for the assessment and a new risk assessment may be needed to be done. Blood sample and clinical assessment |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Specificity and sensibility of the electrodermal hyporeactivity
Time Frame: At 6 and 12 month
|
Correlation between the Edor Test results and suicidal behavior
|
At 6 and 12 month
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The sensibility of the electrodermal hyporeactivity compared with the occurrence of the violent suicidal attempt measured by Columbia-Suicide Severity Rating Scale (C-SSRS)
Time Frame: At 6 month
|
Comparison of test result between patients with history of violent suicidal attempt and patients with history of non violent suicidal
|
At 6 month
|
The sensibility of the electrodermal hyporeactivity compared with the occurrence of the violent suicidal attempt measured by Columbia-Suicide Severity Rating Scale (C-SSRS)
Time Frame: At 6 and 12 month
|
Comparison of test result between patients with history of violent suicidal attempt and patients with history of non violent suicidal
|
At 6 and 12 month
|
Electrodermal activity in depressive and suicidal patients with or without insomnia.
Time Frame: At 6 and 12 month
|
Comparison of test result between patients with insomnia and patient without insomnia.
Insomnia will be evaluated with the "Insomnia severity index" (ISI).
|
At 6 and 12 month
|
Genetic vulnerability to suicidal behavior by polymorphism analysis in blood sample
Time Frame: At the inclusion
|
To study the polymorphisms by blood sample analysis of the promotor of Spermidine/Spermine Acetyltransferase 1 (SAT1), Phenylethanolamine N-Methyltransferase (PNMT) and Noradrenalin Transporter (NAT).
between depressed patients with suicidal behavior and depressed patients without suicidal behavior.
|
At the inclusion
|
The sensibility of the electrodermal hyporeactivity compared with the occurrence of the violent suicidal attempt measured by Risk Rescue Rating Scale (RRRS)
Time Frame: At 6 and 12 month
|
Comparison of test result between patients with history of violent suicidal attempt and patients with history of non violent suicidal
|
At 6 and 12 month
|
The sensibility of the electrodermal hyporeactivity compared with the occurrence of the violent suicidal attempt measured by Beck Scale for Suicidal Intent (SIS).
Time Frame: At 6 and 12 month
|
Comparison of test result between patients with history of violent suicidal attempt and patients with history of non violent suicidal
|
At 6 and 12 month
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- UF 9464
- 2014-A01310-47 (Other Identifier: Agence Nationale de sécurité des Médicaments)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Depression Diagnosis
-
Peking UniversityUnknownDiagnosis and Treatment of Depression
-
Peking UniversityUnknownDiagnosis and Treatment of DepressionChina
-
MYnd AnalyticsUniversity of Ottawa; Canadian Forces Health Services Centre OttawaUnknownDepression | Non-psychotic Diagnosis as Co-morbidityCanada
-
Perry RenshawCompletedDepression | Dual Diagnosis | Drug AddictionUnited States
-
Perry RenshawTerminatedDepression | Substance Use | Dual DiagnosisUnited States
-
Lithuanian University of Health SciencesRecruitingSchizophrenia | Cognitive Deficit | Negative Symptoms in Schizophrenia | Depressive Symptoms Due to Primary Psychotic Disorder (Diagnosis)Lithuania
-
Seinajoki Central HospitalTampere UniversityCompletedAnxiety Disorders | Major Depression | Dual Diagnosis | Substance Related DisordersFinland
-
Beytepe Murat Erdi Eker State HospitalCompletedAnterior Segment Ischemia (Diagnosis)
-
Identifai GeneticsRecruitingGenetics | Prenatal DiagnosisUnited States
-
Ankara Education and Research HospitalCompletedDiagnosis | Axilla; BreastTurkey
Clinical Trials on EDOR test
-
Groupe Hospitalier Mutualiste de GrenobleFondation de l'AvenirCompleted
-
Yonsei UniversityCompletedPostprandial Hyperglycemia
-
Guven Health GroupCompletedAthletic Performance | Physical Fitness | Handball Players | Cross-sectional StudiesTurkey
-
French National Agency for Research on AIDS and...Completed
-
Recep Tayyip Erdogan University Training and Research...Completed
-
Clinical Nutrition Research Centre, SingaporeCompleted
-
University of FloridaCompletedParkinson Disease (PD)United States
-
University of MichiganCompletedAntidepressants Causing Adverse Effects in Therapeutic UseUnited States
-
University of BaghdadCompletedSexual Behavior | Sexual Orientation Conflict Disorder | Sexual Arousal Disorder | Sexual Orientation | Sexual; Orientation, Relationship DisorderIraq